Home » Osteotech’s Biocomposite Receives FDA Clearance
Osteotech’s Biocomposite Receives FDA Clearance
The FDA has granted 510(k) clearance to Osteteotech for its Plexur M biocomposite for use in spinal applications.
The product may be used with autograft as a bone void filler in the spine. It is the second bone-polymer biocomposite developed under the company’s Plexur technology, Osteotech said.
In March, the company received FDA clearance to use the product in filling bony gaps in the pelvis and extremities.
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May